Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • BackgroundSubstantial weight gain is common with many atypical antipsychotics.AimsTo evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.MethodSurvival analysis assessed time to potentially clinically significant weight gain (⩾7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.ResultsAfter 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).ConclusionsOlanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

authors

  • Zipursky, Robert
  • Gu, Hongbin
  • Green, Alan I
  • Perkins, Diana O
  • Tohen, Mauricio F
  • McEvoy, Joseph P
  • Strakowski, Stephen M
  • Sharma, Tonmoy
  • Kahn, René S
  • Gur, Raquel E
  • Tollefson, Gary D
  • Lieberman, Jeffrey A

publication date

  • December 2005